<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0484-7903</journal-id>
<journal-title><![CDATA[Revista mexicana de anestesiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. anestesiol.]]></abbrev-journal-title>
<issn>0484-7903</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Anestesiología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0484-79032021000300229</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Use of sugammadex in acute intermittent porphyria]]></article-title>
<article-title xml:lang="es"><![CDATA[Uso de sugammadex en la porfiria aguda intermitente]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tinoco]]></surname>
<given-names><![CDATA[Joana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Eloy]]></surname>
<given-names><![CDATA[André]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Regufe]]></surname>
<given-names><![CDATA[Rita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rosinha]]></surname>
<given-names><![CDATA[Daniela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Taleco]]></surname>
<given-names><![CDATA[Tiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva-Duarte]]></surname>
<given-names><![CDATA[João]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Setúbal Hospital Center São Bernardo Hospital Department of Anesthesiology]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2021</year>
</pub-date>
<volume>44</volume>
<numero>3</numero>
<fpage>229</fpage>
<lpage>232</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0484-79032021000300229&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0484-79032021000300229&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0484-79032021000300229&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Porphyrias are a group of rare diseases, which include acute intermittent porphyria. It is essential for the anesthesiologist to identify acute porphyrias and to recognize a porphyric crises. These can be triggered by several factors, which can be present throughout the perioperative period. A 70-year-old male, ASA III, with a personal history of acute intermittent porphyria and ischemic heart disease, scheduled for laparoscopic sigmoidectomy. Prolonged fasting, dehydration and potentially porphyrinogenic drugs were avoided. General anesthesia was induced with fentanyl, lidocaine, propofol and rocuronium and maintained with desflurane. The decision to reverse the neuromuscular blockade with sugammadex was considered due to the benefits over risks of this drug when compared to neostigmine (associated with atropine) and the description of its use without harm in two cases of variegate porphyria. The following paper emphasize the importance of careful anesthetic management throughout the perioperative period and describe a case of successful reversal of neuromuscular block with sugammadex, highlighting this case as the first case reported of its use in acute intermittent porphyria.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Las porfirias son un grupo de enfermedades raras, entre las que se encuentra la porfiria aguda intermitente. Es fundamental que el anestesista identifique las porfirias agudas y reconozca una crisis porfírica. Éstos pueden ser desencadenados por varios factores, que pueden estar presentes durante todo el periodo perioperatorio. Varón de 70 años, ASA III, con antecedentes personales de porfiria aguda intermitente y cardiopatía isquémica, programado para sigmoidectomía laparoscópica. Se evitó el ayuno prolongado, la deshidratación y los fármacos potencialmente porfirinógenos. La anestesia general se indujo con fentanilo, lidocaína, propofol y rocuronio y se mantuvo con desflurano. La decisión de revertir el bloqueo neuromuscular con sugammadex se consideró debido a los beneficios sobre los riesgos de este fármaco en comparación con la neostigmina (asociada con la atropina) y a la descripción de su uso sin daños en dos casos de porfiria variegada. El siguiente artículo enfatiza la importancia de un manejo anestésico cuidadoso durante todo el periodo perioperatorio y describe un caso de reversión exitosa del bloqueo neuromuscular con sugammadex, destacando este caso como el primero reportado de su uso en porfiria aguda intermitente.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Sugammadex]]></kwd>
<kwd lng="en"><![CDATA[acute intermittent porphyria]]></kwd>
<kwd lng="en"><![CDATA[anesthesia management]]></kwd>
<kwd lng="en"><![CDATA[case report]]></kwd>
<kwd lng="es"><![CDATA[Sugammadex]]></kwd>
<kwd lng="es"><![CDATA[porfiria intermitente aguda]]></kwd>
<kwd lng="es"><![CDATA[manejo de la anestesia]]></kwd>
<kwd lng="es"><![CDATA[informe de caso]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stein]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Badminton]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Rees]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update review of the acute porphyrias]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2017</year>
<volume>176</volume>
<page-range>527-38</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ajayi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ward]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Summers]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pathophysiology, pharmacology and treatment of acute intermittent porphyria: a patient case description and recommendations from the current literature]]></article-title>
<source><![CDATA[J Explor Res Pharmacol]]></source>
<year>2017</year>
<volume>2</volume>
<page-range>49-53</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sood]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
</person-group>
<source><![CDATA[Pathogenesis, clinical manifestations, and diagnosis of acute intermittent porphyria]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Waltham, MA ]]></publisher-loc>
<publisher-name><![CDATA[Walters Kluwer Health]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Findley]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Philips]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cole]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Porphyrias: implications for anaesthesia, critical care, and pain medicine]]></article-title>
<source><![CDATA[Contin Educ Anaesth Crit Care Pain]]></source>
<year>2012</year>
<volume>12</volume>
<page-range>128-33</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramanujam]]></surname>
<given-names><![CDATA[VS]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[KE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Porphyria diagnostics-Part 1: a brief overview of the porphyrias]]></article-title>
<source><![CDATA[Curr Protoc Hum Genet]]></source>
<year>2015</year>
<volume>86</volume>
<page-range>17.20.1-17.20.26</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<source><![CDATA[European Porphyria Network]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<source><![CDATA[American Porphyria Foundation]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<source><![CDATA[The Norwegian Porphyria Centre (NAPOS)]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ku&#378;minski]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aporowicz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elective cholecystectomy performed on patient with variegate porphyria-propofol based total intravenous anesthesia with target-controlled infusion]]></article-title>
<source><![CDATA[J Clin Anesth]]></source>
<year>2016</year>
<volume>35</volume>
<page-range>114-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crespo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Herrero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anestesia general en pacientes con porfiria]]></article-title>
<source><![CDATA[Revista Electrónica de AnestesiaR (RealR)]]></source>
<year>2018</year>
<volume>10</volume>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nag]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Shetti]]></surname>
<given-names><![CDATA[AN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sugammadex: a revolutionary drug in neuromuscular pharmacology]]></article-title>
<source><![CDATA[Anesth Essays Res]]></source>
<year>2013</year>
<volume>7</volume>
<page-range>302-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buijs]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Scholten]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ros]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful administration of sugammadex in a patient with acute porphyria - A case report]]></article-title>
<source><![CDATA[Eur J Anaesthesiol]]></source>
<year>2014</year>
<volume>31</volume>
<page-range>439-41</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aoki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Atsumi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kora]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Koh]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yokoyama]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sugammadex and amino acid infusion can contribute to safe anesthetic management of variegate porphyria]]></article-title>
<source><![CDATA[JA Clin Rep]]></source>
<year>2018</year>
<volume>4</volume>
<page-range>49</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
